XML 24 R11.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Information

3. Segment Information

 

The Company’s chief operating decision maker (“CODM”) has been identified as the Company’s Chief Executive Officer (“CEO”). The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently has a single operating segment which is comprised of the consolidated financial results of the Company.

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.

  

             
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2025   2024   2025   2024 
                 
Clinical and related oversight costs  $13,424   $250,342   $40,894   $358,319 
Preclinical research focused on development of additional novel anti-cancer compounds   22,211    90,821    92,573    300,130 
Compound maintenance   7,480    9,062    60,563    18,932 
Regulatory service costs   7,581    11,405    8,771    14,021 
Total research and development costs  $50,696   $361,630   $202,801   $691,402 

 

The following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and 2024 based on the respective geographical regions where such costs were incurred.

 

             
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2025   2024   2025   2024 
                 
United States  $46,305   $278,808   $146,804   $427,736 
Spain   4,391    6,544    55,997    51,022 
China   —    —    —    2,282 
Netherlands   —    76,278    —    210,362 
Total research and development costs  $50,696   $361,630   $202,801   $691,402 

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.

 

             
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2025   2024   2025   2024 
                 
Compensation to related parties:                    
Cash-based  $217,416   $176,226   $449,432   $566,624 
Stock-based   776,611    106,827    1,144,348    340,445 
Patent and licensing legal and filing fees and costs   16,853    45,415    90,239    192,238 
Other consulting and professional fees   538,822    117,893    920,689    481,865 
Insurance expense   64,277    116,440    192,830    370,167 
Other costs and expenses, net   136,679    58,826    282,764    316,551 
Total general and administrative costs  $1,750,658   $621,627   $3,080,302   $2,267,890 

 

 

The following table presents the Company’s total assets by segment at September 30, 2025 and December 31, 2024.

 

  

September 30,

2025

  

December 31,

2024

 
         
Research and development assets  $10,412   $39,298 
Corporate assets (primarily cash and digital assets)   5,423,264    1,106,205 
Total assets  $5,433,676   $1,145,503